Malignant Mesothelioma Clinical Trial Combines Immunotherapy Drugs

Chatwal, Monica Sheila; Tanvetyanon, Tawee

doi:10.2217/imt-2017-0177

Cited by 8 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immune checkpoint inhibitors targeting the PD-L1/PD-1 pathway have recently been used to treat advanced MPM, and the efficacy is being investigated in several clinical trials. Some patients with advanced MPM benefited from immunotherapy with anti-PD-L1/PD-1 inhibitors [14,15,16,17,30,31,32,33]. A phase II clinical trial (NCT02628067; KEYNOTE-158) to investigate the efficacy of pembrolizumab (anti-PD-1) in advanced solid tumors, including MPM, is ongoing; patients are encouraged to participate in this trial to facilitate advancement in the treatment of MPM.…”

Section: Programmed Death-ligand 1 In Non-small Cell Lung Cancer Amentioning

confidence: 99%

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

et al. 2018

View full text Add to dashboard Cite

The programmed death-ligand 1(PD-L1)/PD-1 pathway is an immunological checkpoint in cancer cells. The binding of PD-L1 and PD-1 promotes T-cell tolerance and helps tumor cells escape from host immunity. Immunotherapy targeting the PD-L1/PD-1 axis has been developed as an anti-cancer therapy and used in treating advanced human non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Yes-associated protein (YAP) is a key mediator of the Hippo/YAP signaling pathway, and plays important roles in promoting cancer development, drug resistance and metastasis in human NSCLC and MPM. YAP has been suggested as a new therapeutic target in NSCLC and MPM. The role of YAP in regulating tumor immunity such as PD-L1 expression has just begun to be explored, and the correlation between YAP-induced tumorigenesis and host anti-tumor immune responses is not well known. Here, we review recent studies investigating the correlation between YAP and PD-L1 and demonstrating the mechanism by which YAP regulates PD-L1 expression in human NSCLC and MPM. Future work should focus on the interactions between Hippo/YAP signaling pathways and the immune checkpoint PD-L1/PD-1 pathway. The development of new synergistic drugs for immune checkpoint PD-L1/PD-1 blockade in NSCLC and MPM is warranted.

show abstract

Section: Programmed Death-ligand 1 In Non-small Cell Lung Cancer Amentioning

confidence: 99%

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Anti-PD-1 and anti-PD-L1 immunotherapy protocols (such as nivolumab or pembrolizumad) have been developed and used to restore immune edition in cancers [ Figure 2]. This process is called immune checkpoint blockade (ICB) and, in the last few years, this new treatment has been tested and shown promising results in many different types of cancers such as: non-small cell lung carcinoma (NSCLC), melanoma, mesothelioma, renal cell carcinoma (RCC), bladder cancer, head and neck squamous cell carcinoma (HNSCC) [14][15][16][17][18][19] . Unfortunately, although some very interesting results were obtained in some patients, resistance to ICB are observed in a large percentage of cases.…”

Section: Resistance To Immunotherapy In Cancersmentioning

confidence: 99%

Epigenetics, a key player of immunotherapy resistance

Peixoto¹,

Renaude²,

Boyer-Guittaut³

et al. 2018

CDR

View full text Add to dashboard Cite

In 2018, the Nobel Prize in medicine was awarded to James P. Allison and Tasuku Honjo for their work on the description of immune checkpoint inhibitors which contributed to the development of new anti-cancer immunotherapies. However, although these new therapeutic strategies, which are designed to limit immune escape of cancer cells, have been used or tested successfully in many different cancers, a large proportion of patients have been described to resist and not respond to these new treatments. The new incoming challenge is now therefore to overcome these resistance and new recent data presented epigenetic modifications as promising targets to restore anti-tumor immunity. Indeed, both DNA methylation and post-translational histone modifications have been described to regulate immune checkpoint inhibitor expression, tumor-associated antigen presentation or cancer cell editing by the immune system and therefore establishing epigenetic drugs as a potential complement to immunotherapies to improve their efficiency.

show abstract

“…Our second-most-read article was an editorial that evaluated the effect that combining immunotherapy checkpoint inhibitors PD1, PD-L1 and CTLA-4 have on mesothelioma [2]. Written by Monica Chatwal et al, this article concluded that this method of treatment is showing promise but further study is needed.…”

Section: Content Highlightsmentioning

confidence: 99%

Immunotherapy Foreword 2018

Gregg

2018

Immunotherapy

View full text Add to dashboard Cite

To all of our readers, the Future Medicine editorial office would like to thank you for your continued readership over 2018 and I hope you have a fantastic Christmas and New Year. I would also like to thank our esteemed editorial board, peer reviewers and contributing authors for their continued support. We very much look forward to working with you all in 2019 and seeing the journal continue to progress. In this foreword, we will present some highlights from the last 12 months in addition to looking forward to the year ahead.

show abstract

Malignant Mesothelioma Clinical Trial Combines Immunotherapy Drugs

Cited by 8 publications

References 18 publications

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

Epigenetics, a key player of immunotherapy resistance

Immunotherapy Foreword 2018

Contact Info

Product

Resources

About